IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Mylan to Buy Merck KGaA’s Generics Unit for $6.7 Billion

1:39 PM MDT | July 25, 2007 | Alex Scott

Mylan Laboratories (Canonsburg, PA) says it has agreed to buy Merck KGaA’s generic pharmaceuticals business for €4.9 billion ($6.7 billion) in cash. The sale price is in line with market expectations (CW, May 9, p. 6). Merck KGaA’s generics unit generated sales in 2006 of €1.8 billion, placing it fourth in the market behind Barr Pharmaceuticals (Woodcliff Lake, NJ), Novartis, and Teva Pharmaceutical Industries (Petach Tikva, Israel). Mylan and the Merck KGaA business will have a combined annual Ebitda of about $1 billion and sales of about...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa